Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern

By J. Pitout, Kevin B. Laupland. 2008

1,864 citations recorded by the source corpus.

Subfields: Endocrinology, Epidemiology, Molecular Medicine

View Paper: https://www.semanticscholar.org/paper/58f280cab7f30ac91365d7296634eb0f941d0672

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology

1. P. Nordmann
2. L. Poirel
3. J. Pitout
4. David L. Paterson
5. Amy Mathers
6. G. Peirano
7. T. Naas
8. C. Giske

In Epidemiology

1. P. Nordmann
2. J. Pitout
3. B. Spellberg
4. David L. Paterson
5. H. Boucher

In Molecular Medicine

1. P. Nordmann
2. L. Poirel
3. J. Pitout
4. Amy Mathers
5. G. Peirano
6. David L. Paterson
7. T. Naas
8. J. González-Alba

Citations in the corpus

• CTX-M Enzymes: Origin and Diffusion (2012, background): “…class A β-lactamases, the extended-spectrum β-lactamases (ESBLs) which are able to hydrolyze expandedspectrum cephalosporins (such as cefotaxime, ceftriaxone, ceftazidime, or cefepime) and monobactams (aztreonam) represent a public health concern (Coque et al., 2008a; Pitout and Laupland, 2008).”
• Extended-spectrum β-lactamase-producing and AmpC-producing Escherichia coli from livestock and companion animals, and their putative impact on public health: a global perspective. (2012, positive): “ESBLs confer resistance to oxyiminocephalosporins, and often express a multidrug-resistant phenotype, leaving only limited therapeutic options [10].”
• Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. (2009, background): “The number of enzymes and the number of organisms that exhibit cross-resistance to other classes of antimicrobials is growing, which makes selection of therapy even more challenging [4, 11, 27, 59 , 60].”
• The Role of Epidemic Resistance Plasmids and International High-Risk Clones in the Spread of Multidrug-Resistant Enterobacteriaceae (2015, background): “coli are often co-resistant to various antibiotic classes that includes cotrimoxazole, the aminoglycosides and the fluoroquinolones (15).”
• Global Spread of Carbapenemase-producing Enterobacteriaceae (2011, background): “Since 2000, spread of community-acquired enterobacterial isolates (Escherichia coli) that produce extended-spectrum β-lactamases (ESBLs) capable of hydrolyzing almost all cephalosporins except carbapenems has been reported worldwide (1).”
• Antibiotic resistance and extended spectrum beta-lactamases: Types, epidemiology and treatment. (2015, background): “These enzymes are known as extended-spectrum b-lactamases (ESBLs) (Pitout and Laupland, 2008; Paterson and Bonomo, 2005).”
• Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. (2012, background): “) require special mention; these organisms can be resistant to all currently available antimicrobial agents or remain susceptible only to older, potentially more toxic agents such as the polymyxins, leaving limited and suboptimal options for treatment [5–7].”